Surrey Heartlands

Joint Formulary & PAD

Latanoprost with netarsudil - Glaucoma / ocular hypertension

You are here : Home > Formulary Search > Latanoprost with netarsudil - Glaucoma / ocular hypertension

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Eye drops
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NICE
Restrictions / Comments :
Important
Treatment should be initiated by specialist clinicians and at least 1 month supply should be provided at initiation before transfer of care.
Documents :
 
Evidence Review
Latanoprost-netarsudil in Glaucoma - NICE TA briefing - January 2025.pdf
Webpage
NICE TA 1009 - Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
Webpage
Decision support tool: making a decision about open-angle glaucoma - NHS England

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Latanoprost with netarsudil
Indication :
Glaucoma / ocular hypertension
Group Name :
Keywords :
primary open angle, ophthalmology, eyes, NICE
Brand Names Include :
Roclanda
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Glaucoma / ocular hypertension
Supporting Documents :
3

Other Indications

Below are listed other indications that Latanoprost with netarsudil is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Glaucoma / ocular hypertension.

Committee Recommendations (1)

01 Jan 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves latanoprost with netarsudil for previously treated primary open-angle glaucoma or ocular hypertension as recommended by NICE TA1009

Latanoprost -netasurdil for this indication will be considered as BLUE on the traffic light system, treatment should be initiated by specialist clinicians, and at least 1 month supply should be provided at initiation before transfer of care.